OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites

Launched by NATIONAL MEDICAL RESEARCH RADIOLOGICAL CENTRE OF THE MINISTRY OF HEALTH OF RUSSIA · Feb 28, 2025

Keywords

ClinConnect Summary

The OLIGO-10 clinical trial is studying a type of radiation therapy called stereotactic ablative radiation therapy for patients with metastatic cancer who have 6 to 10 metastases, which are cancer spots that have spread from the original tumor to other parts of the body. This trial aims to find out if this radiation treatment can help improve patient safety and effectiveness while they continue their current drug therapies, such as chemotherapy or immunotherapy. The hope is to provide a new treatment option for patients who may not have many choices left.

To be eligible for this trial, participants need to have persistent or progressive cancer with 6 to 10 metastases, and they should not be able to have all their metastatic lesions surgically removed. Other key criteria include having a life expectancy of more than six months and not having certain complications, such as large brain metastases or previous radiation treatment for their cancer. Participants in this trial can expect to receive targeted radiation therapy while remaining on their existing medication, and they will be closely monitored for safety and effectiveness throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ECOG status 0-3
• • Persistent or progressive cancer disease with 6 to 10 metastases
• • ≤ 5 metastases in one organ
• • Life expectancy \> 6 months for intracranial lesions
• • Inability to surgically resect all metastatic lesions
• • Positive tumor board decision for trial inclusion
• • Signed informed consent
• Exclusion Criteria:
• • ECOG status 4
• • De novo metastatic disease
• • Radiological complete response after drug therapy
• • Brain metastasis only
• • Brain metastasis \> 3 cm, requiring neurosurgery
• • Size of any metastasis \> 5 cm
• • Previous radiation therapy for any metastatic site
• • Leptomeningeal, pleural, or peritoneal carcinomatosis
• • Spinal cord compression, requiring neurosurgery
• • Invasion of great vessels, skin, or GI tract
• • Negative tumor board decision for trial inclusion
• • Unsigned informed consent